title: Conditional deletion of Jak2 reveals an essential role in hematopoiesis throughout mouse ontogeny: implications for Jak2 inhibition in humans.
abstract: Germline deletion of Jak2 in mice results in embryonic lethality at E12.5 due to impaired hematopoiesis. However, the role that Jak2 might play in late gestation and postnatal life is unknown. To understand this, we utilized a conditional knockout approach that allowed for the deletion of Jak2 at various stages of prenatal and postnatal life. Specifically, Jak2 was deleted beginning at either mid/late gestation (E12.5), at postnatal day 4 (PN4), or at ∼2 months of age. Deletion of Jak2 beginning at E12.5 resulted in embryonic death characterized by a lack of hematopoiesis. Deletion beginning at PN4 was also lethal due to a lack of erythropoiesis. Deletion of Jak2 in young adults was characterized by blood cytopenias, abnormal erythrocyte morphology, decreased marrow hematopoietic potential, and splenic atrophy. However, death was observed in only 20% of the mutants. Further analysis of these mice suggested that the increased survivability was due to an incomplete deletion of Jak2 and subsequent re-population of Jak2 expressing cells, as conditional deletion in mice having one floxed Jak2 allele and one null allele resulted in a more severe phenotype and subsequent death of all animals. We found that the deletion of Jak2 in the young adults had a differential effect on hematopoietic lineages; specifically, conditional Jak2 deletion in young adults severely impaired erythropoiesis and thrombopoiesis, modestly affected granulopoiesis and monocytopoiesis, and had no effect on lymphopoiesis. Interestingly, while the hematopoietic organs of these mutant animals were severely affected by the deletion of Jak2, we found that the hearts, kidneys, lungs, and brains of these same mice were histologically normal. From this, we conclude that Jak2 plays an essential and non-redundant role in hematopoiesis during both prenatal and postnatal life and this has direct implications regarding the inhibition of Jak2 in humans.
authors.affiliation: Department of Physiology and Functional Genomics, University of Florida College of Medicine, Gainesville, Florida, United States of America.
authors.forename: Sung O
authors.initials: SO
authors.lastname: Park
authors.forename: Heather L
authors.initials: HL
authors.lastname: Wamsley
authors.forename: Kyungmi
authors.initials: K
authors.lastname: Bae
authors.forename: Zhongbo
authors.initials: Z
authors.lastname: Hu
authors.forename: Xiaomiao
authors.initials: X
authors.lastname: Li
authors.forename: Se-woon
authors.initials: SW
authors.lastname: Choe
authors.forename: William B
authors.initials: WB
authors.lastname: Slayton
authors.forename: S Paul
authors.initials: SP
authors.lastname: Oh
authors.forename: Kay-Uwe
authors.initials: KU
authors.lastname: Wagner
authors.forename: Peter P
authors.initials: PP
authors.lastname: Sayeski
mesh_terms: D000375:Aging / Q000473:pathology; D000740:Anemia / Q000473:pathology; D000818:Animals; D000831:Animals, Newborn; D001772:Blood Cell Count; D020964:Embryo Loss / Q000473:pathology; D047108:Embryonic Development / Q000187:drug effects / Q000235:genetics*; D005260:Female; D019204:GTP-Binding Proteins / Q000378:metabolism; D017353:Gene Deletion; D006410:Hematopoiesis / Q000187:drug effects / Q000235:genetics*; D006412:Hematopoietic Stem Cells / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D006801:Humans; D050856:Interferon Regulatory Factor-1 / Q000378:metabolism; D053614:Janus Kinase 2 / Q000037:antagonists & inhibitors* / Q000235:genetics*; D008214:Lymphocytes / Q000187:drug effects / Q000473:pathology; D051379:Mice; D018345:Mice, Knockout; D023461:Myeloid Progenitor Cells / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D009928:Organ Specificity / Q000187:drug effects; D011247:Pregnancy; D013154:Spleen / Q000473:pathology; D016019:Survival Analysis; D013629:Tamoxifen / Q000494:pharmacology
chemical_list: D050856:Interferon Regulatory Factor-1; C494258:Irf1 protein, mouse; D013629:Tamoxifen; D053614:Janus Kinase 2; D019204:GTP-Binding Proteins; C452200:Gbp2 protein, mouse
references.citation: Blood Rev. 2011 Sep;25(5):229-37
references.pmid: 21742423
references.citation: Lancet. 2005 Mar 19-25;365(9464):1054-61
references.pmid: 15781101
references.citation: Oncogene. 1992 Jul;7(7):1347-53
references.pmid: 1620548
references.citation: Haematologica. 2001 Jan;86(1):52-7
references.pmid: 11146571
references.citation: Br J Haematol. 2006 Aug;134(4):366-84
references.pmid: 16822289
references.citation: Leukemia. 2011 Nov;25(11):1751-9
references.pmid: 21691275
references.citation: Mayo Clin Proc. 2011 Dec;86(12):1188-91
references.pmid: 22034658
references.citation: Nat Med. 2010 Feb;16(2):183-90
references.pmid: 20098430
references.citation: Nature. 2005 Apr 28;434(7037):1144-8
references.pmid: 15793561
references.citation: N Engl J Med. 2012 Mar 1;366(9):844-6
references.pmid: 22375977
references.citation: J Exp Med. 2004 Mar 15;199(6):867-78
references.pmid: 15024050
references.citation: J Mol Cell Cardiol. 2002 Nov;34(11):1443-53
references.pmid: 12431443
references.citation: Blood. 2012 Mar 22;119(12):2721-30
references.pmid: 22279053
references.citation: Cell. 1993 Jul 30;74(2):227-36
references.pmid: 8343951
references.citation: J Biol Chem. 2005 Jun 17;280(24):22788-92
references.pmid: 15863514
references.citation: Cell. 1998 May 1;93(3):385-95
references.pmid: 9590173
references.citation: Clin Cancer Res. 2012 Jun 1;18(11):3008-14
references.pmid: 22474318
references.citation: Cell. 1993 Jul 30;74(2):237-44
references.pmid: 8343952
references.citation: Exp Hematol. 2007 Feb;35(2):214-220
references.pmid: 17258070
references.citation: Cancer Cell. 2005 Apr;7(4):387-97
references.pmid: 15837627
references.citation: N Engl J Med. 2011 Oct 13;365(15):1455-7
references.pmid: 21995409
references.citation: Stem Cells. 1993 Sep;11(5):371-80
references.pmid: 7694720
references.citation: Exp Cell Res. 2006 Sep 10;312(15):2735-44
references.pmid: 16887119
references.citation: Nat Genet. 1999 Jan;21(1):70-1
references.pmid: 9916792
references.citation: Oncogene. 2002 May 13;21(21):3334-58
references.pmid: 12032773
references.citation: Blood. 2010 Aug 5;116(5):793-800
references.pmid: 20457868
references.citation: J Clin Invest. 2008 Mar;118(3):924-34
references.pmid: 18246197
references.citation: Oncogene. 2006 Jun 1;25(23):3316-24
references.pmid: 16418722
references.citation: Exp Hematol. 2010 Dec;38(12):1251-60
references.pmid: 20813153
references.citation: Blood. 2006 Sep 1;108(5):1524-32
references.pmid: 16705093
references.citation: Nat Neurosci. 2012 Oct;15(10):1391-8
references.pmid: 22941110
references.citation: Blood. 1999 Jan 1;93(1):1-14
references.pmid: 9864140
references.citation: Biol Reprod. 2004 Nov;71(5):1469-74
references.pmid: 15215191
references.citation: Genesis. 2004 Sep;40(1):52-7
references.pmid: 15354294
references.citation: Cell. 1998 May 1;93(3):397-409
references.pmid: 9590174
references.citation: Cell Biochem Biophys. 2004;41(2):207-32
references.pmid: 15475610
references.citation: Kidney Int. 2009 Jan;75(2):227-34
references.pmid: 18818682
references.citation: N Engl J Med. 2005 Apr 28;352(17):1779-90
references.pmid: 15858187